Published in Immunol Allergy Clin North Am on May 01, 2007
Dual function of a bee venom serine protease: prophenoloxidase-activating factor in arthropods and fibrin(ogen)olytic enzyme in mammals. PLoS One (2010) 1.00
The use of concentrated heat after insect bites/stings as an alternative to reduce swelling, pain, and pruritus: an open cohort-study at German beaches and bathing-lakes. Clin Cosmet Investig Dermatol (2011) 0.83
Anaphylaxis to insect venom allergens: role of molecular diagnostics. Curr Allergy Asthma Rep (2015) 0.80
Diagnostics in Hymenoptera venom allergy: current concepts and developments with special focus on molecular allergy diagnostics. Allergo J Int (2017) 0.78
The correlation between anti phospholipase A2 specific IgE and clinical symptoms after a bee sting in beekeepers. Postepy Dermatol Alergol (2016) 0.75
The neurotoxicological effects of mastoparan Polybia-MPII at the murine neuromuscular junction: an ultrastructural and immunocytochemical study. Histochem Cell Biol (2009) 0.75
Management of insect sting hypersensitivity: an update. Allergy Asthma Immunol Res (2013) 0.75
Six years of INSTAND e. V. sIgE proficiency testing: An evaluation of in vitro allergy diagnostics. Allergo J Int (2017) 0.75
Transient Unexplained Shock in 30-year-old Trauma Patient. Emerg (Tehran) (2014) 0.75
Analysis of serum peptidome patterns of patients stung by honey bees. J Res Med Sci (2013) 0.75
Improved efficacy of allergen-specific immunotherapy by JAK inhibition in a murine model of allergic asthma. PLoS One (2017) 0.75
Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol (2006) 6.64
Insect-sting challenge in 324 subjects with a previous anaphylactic reaction: current criteria for insect-venom hypersensitivity do not predict the occurrence and the severity of anaphylaxis. J Allergy Clin Immunol (1994) 5.14
The diagnosis and management of anaphylaxis: an updated practice parameter. J Allergy Clin Immunol (2005) 4.07
Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N Engl J Med (2004) 3.16
Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol (2006) 2.80
Role of interleukin 10 in specific immunotherapy. J Clin Invest (1998) 2.57
The value of immunotherapy with venom in children with allergy to insect stings. N Engl J Med (1990) 2.35
Diagnosis of Hymenoptera venom allergy. Allergy (2005) 2.34
Immunoglobulin E antibodies that crossreact with vegetable foods, pollen, and Hymenoptera venom. J Allergy Clin Immunol (1981) 2.18
Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol (1996) 2.13
A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med (1978) 2.08
Studies of 400 Hymenoptera sting deaths in the United States. J Allergy Clin Immunol (1973) 1.89
Epidemiology of insect venom sensitivity. JAMA (1989) 1.83
Insect sting allergy and venom immunotherapy: a model and a mystery. J Allergy Clin Immunol (2005) 1.74
Natural history of insect sting allergy: relationship of severity of symptoms of initial sting anaphylaxis to re-sting reactions. J Allergy Clin Immunol (1992) 1.55
Natural history of Hymenoptera venom sensitivity in adults. J Allergy Clin Immunol (1997) 1.55
Intentional diagnostic insect sting challenges: a medical and ethical issue. J Allergy Clin Immunol (1993) 1.54
Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial. Lancet (2003) 1.54
Clinical correlation of the venom-specific IgG antibody level during maintenance venom immunotherapy. J Allergy Clin Immunol (1992) 1.48
Allergens in Hymenoptera venoms. XXIII. Venom content of imported fire ant whole body extracts. Ann Allergy (1991) 1.48
Reproducibility of skin testing and serum venom specific IgE in Hymenoptera venom allergy. Ann Allergy Asthma Immunol (2006) 1.40
Structure and biology of stinging insect venom allergens. Int Arch Allergy Immunol (2000) 1.33
Late-onset allergic reactions, including serum sickness, after insect stings. J Allergy Clin Immunol (1989) 1.20
The Hymenoptera venom study I, 1979-1982: demographics and history-sting data. J Allergy Clin Immunol (1988) 1.16
Honeybee venom allergy: results of a sting challenge 1 year after stopping successful venom immunotherapy in 86 patients. J Allergy Clin Immunol (1991) 1.16
INSECT-STING ALLERGY: QUESTIONNAIRE STUDY OF 2,606 CASES. JAMA (1965) 1.13
Regimens of Hymenoptera venom immunotherapy. Ann Intern Med (1980) 1.12
Antibody binding to venom carbohydrates is a frequent cause for double positivity to honeybee and yellow jacket venom in patients with stinging-insect allergy. J Allergy Clin Immunol (2001) 1.11
Multicenter study of emergency department visits for insect sting allergies. J Allergy Clin Immunol (2005) 1.06
Development and validation of a health-related quality-of-life questionnaire in patients with yellow jacket allergy. J Allergy Clin Immunol (2002) 1.06
Expanding habitat of the imported fire ant (Solenopsis invicta): a public health concern. J Allergy Clin Immunol (2000) 1.05
Stinging insect hypersensitivity: a practice parameter update. J Allergy Clin Immunol (2004) 1.03
The Hymenoptera venom study. III: Safety of venom immunotherapy. J Allergy Clin Immunol (1990) 1.02
Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom. J Allergy Clin Immunol (2002) 1.01
Side-effects of insect venom immunotherapy: results from an EAACI multicenter study. European Academy of Allergology and Clinical Immunology. Allergy (2000) 1.01
Clinical and immunologic studies of patients with large local reactions following insect stings. J Allergy Clin Immunol (1980) 0.98
Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol (1992) 0.97
Frequency of Hymenoptera allergy in an atopic and normal population. J Allergy Clin Immunol (1972) 0.97
The sting challenge test in Hymenoptera venom allergy. Position paper of the Subcommittee on Insect Venom Allergy of the European Academy of Allergology and Clinical Immunology. Allergy (1996) 0.96
Rapid Hymenoptera venom immunotherapy: comparative safety of three protocols. Clin Exp Allergy (1993) 0.95
Survey of patients after discontinuing venom immunotherapy. J Allergy Clin Immunol (2000) 0.94
Should beta-blockers be given to patients with heart disease and peanut-induced anaphylaxis? A decision analysis. J Allergy Clin Immunol (2004) 0.91
Imported fire ant immunotherapy: effectiveness of whole body extracts. J Allergy Clin Immunol (1992) 0.87
Evaluation of decline in serum venom-specific IgE as a criterion for stopping venom immunotherapy. J Allergy Clin Immunol (1986) 0.87
Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients. J Allergy Clin Immunol (1998) 0.87
Safety and efficacy of an imported fire ant rush immunotherapy protocol with and without prophylactic treatment. J Allergy Clin Immunol (2002) 0.87
Immunotherapy in bee sting hypersensitivity. Bee venom versus wholebody extract. Allergy (1979) 0.87
Level of osteopontin is increased after bee venom immunotherapy. J Allergy Clin Immunol (2005) 0.86
Further observations of stopping venom immunotherapy: comparison of patients stopped because of a fall in serum venom-specific IgE to insignificant levels with patients stopped prematurely by self-choice. J Allergy Clin Immunol (1989) 0.86
A prospective study of the natural history of large local reactions after Hymenoptera stings in children. J Pediatr (1984) 0.85
Fatal reactions to hymenoptera stings. Allergy Asthma Proc (2003) 0.85
Duration of venom immunotherapy: relationship to the severity of symptoms of initial insect sting anaphylaxis. J Allergy Clin Immunol (1993) 0.84
Timing of venom skin tests and IgE determinations after insect sting anaphylaxis. J Allergy Clin Immunol (1997) 0.84
Natural history of large local reactions from stinging insects. J Allergy Clin Immunol (1984) 0.84
The natural history of exposure to the imported fire ant (Solenopsis invicta). J Allergy Clin Immunol (1995) 0.83
Lack of reproducibility of a single negative sting challenge response in the assessment of anaphylactic risk in patients with suspected yellow jacket hypersensitivity. J Allergy Clin Immunol (1994) 0.82
Discontinuing venom immunotherapy: extended observations. J Allergy Clin Immunol (1998) 0.82
Rapid venom immunotherapy is safe for routine use in the treatment of patients with Hymenoptera anaphylaxis. Ann Allergy (1994) 0.81
Unusual reactions following insect stings. Clinical features and immunologic analysis. J Allergy Clin Immunol (1977) 0.80
Diagnostic methods for insect sting allergy. Curr Opin Allergy Clin Immunol (2004) 0.80
An epidemiologic study of insect allergy in children. I. Characteristics of the disease. J Pediatr (1982) 0.79
Clinical and entomological factors influence the outcome of sting challenge studies. J Allergy Clin Immunol (2006) 0.79
Ant allergy in Asia and Australia. Curr Opin Allergy Clin Immunol (2004) 0.78
Discontinuation of bee venom immunotherapy in children and adolescents. J Pediatr (1985) 0.77
Treatment failures with whole-body extract therapy of insect sting allergy. JAMA (1981) 0.76
Wasp sting-associated cold urticaria. Allergy (1997) 0.76
Responsibility for quality IgE antibody results rests ultimately with the referring physician. Ann Allergy Asthma Immunol (2001) 0.76